[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"coronary-artery-stenosis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:coronary-artery-stenosis":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,12,0,[8,41,71,100,131,159,181,197,229,251,281,302],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":4},"100053574","coronary-laser-atherectomy-system-for-treatment-of-coronary-artery-stenosis-shine-100053574",false,"NCT07697638","Coronary Laser Atherectomy System for Treatment of Coronary Artery Stenosis (SHINE)","A Prospective, Multicenter Clinical Trial in Evaluating the Safety and Efficacy of the Coronary Laser Atherectomy System in Patients With Coronary Artery Stenosis (SHINE)","SHINE","Inclusion Criteria:\n\nClinical Inclusion Criteria:\n\n1. Age 18-85 years, male or female.\n2. Coronary angiography confirms the need for PCI.\n3. Diagnosed with stable angina, silent myocardial ischemia, unstable angina, non-ST-segment elevation myocardial infarction, or STEMI \\>7 days.\n4. During PCI, the investigator determines that laser atherectomy is required for lesion pretreatment.\n5. Able to understand the purpose of the trial, voluntarily participate and sign the informed consent form acknowledging the risks and benefits described in the informed consent document, and able to complete clinical follow-up as required.\n\nAngiographic Inclusion Criteria (visual estimate):\n\n1. Target lesion reference vessel diameter (RVD) ≥2.00 mm by visual estimate.\n2. Target lesion stenosis ≥70% (visual estimate), or ≥50% and \\\u003C70% with evidence of ischemia. Evidence of ischemia includes any of the following:\n\n   * Positive exercise stress test\n   * FFR or QFR ≤0.8\n   * Meets severe stenosis criteria by intracoronary imaging (IVUS or OCT): MLA \\\u003C2.4 mm² for vessels with diameter \\\u003C3.0 mm; MLA \\\u003C2.7 mm² for vessels with diameter 3.0-3.5 mm; MLA \\\u003C3.6 mm² for vessels with diameter \\>3.5 mm\n3. Target lesion is a small-diameter predilation balloon (balloon diameter ≤1.5 mm), uncrossable and\u002For undilatable lesion (undilatable under stent post-dilation balloon rated burst pressure and\u002For special circumstances unsuitable for dilation), including calcified lesions, CTO lesions, in-stent restenosis, stent underexpansion, and high thrombus burden lesions.\n4. Guidewire successfully passes through the true lumen of the target lesion without NHLBI type C or higher dissection.\n\nExclusion Criteria:\n\nClinical Exclusion Criteria:\n\n1. Hemodynamic instability or severely reduced exercise tolerance (NYHA Class III or IV).\n2. Severe heart failure with reduced ejection fraction (LVEF \\\u003C30%).\n3. Intracardiac thrombus on echocardiography within 30 days prior to enrollment.\n4. Has received an organ transplant or is awaiting an organ transplant.\n5. Currently receiving chemotherapy or scheduled to receive chemotherapy within 30 days before or after the baseline procedure.\n6. Has a bleeding diathesis, contraindication to antiplatelet or anticoagulant therapy, or is unable to receive antithrombotic therapy.\n7. Chronic renal insufficiency with serum creatinine \\>2.5 mg\u002FdL (or 221 µmol\u002FL).\n8. Cerebrovascular accident (CVA), transient ischemic attack (TIA), or permanent neurological deficit that may preclude compliance with the protocol within the past 6 months.\n9. Unconscious or requiring circulatory support or mechanical ventilation before PCI.\n10. The target vessel (including side branches) has received any PCI within 1 month prior to the baseline procedure.\n11. Planned interventional or cardiac surgical procedure within 30 days after baseline procedure.\n12. Prior coronary intravascular brachytherapy at any time.\n13. Allergy to medications or devices required during PCI (including but not limited to rapamycin, paclitaxel, dual antiplatelet agents, polyamide, polyurethane, PTFE, or stainless steel).\n14. Other severe medical conditions (e.g., cancer, congestive heart failure) with life expectancy \\\u003C12 months.\n15. Current substance abuse or addiction (e.g., alcohol, cocaine, heroin).\n16. Currently participating in another investigational drug or device trial that has not reached its primary endpoint, or planning to participate in another investigational drug or device trial within 6 months after the baseline procedure.\n17. Plans to conceive within 6 months after baseline procedure.\n18. Pregnant or breastfeeding women (pregnancy test required within 7 days before baseline procedure for women of childbearing potential).\n19. The investigator determines that the subject is unsuitable for enrollment.\n\nAngiographic Exclusion Criteria (visual estimate):\n\n1. Target lesion meets any of the following criteria:\n\n   -≥2 target lesions requiring treatment during the baseline procedure\n   * Ostial lesion (within 3 mm of the ostium)\n   * Medina type \"x, x, 1\" bifurcation lesion\n   * Intimal dissection (NHLBI type C or higher)\n   * Guidewire-uncrossable total occlusion\n   * Severely angulated lesion\n2. Unprotected left main coronary artery disease (\\>50% diameter stenosis).\n3. The target vessel has other clinically significant lesions that may require intervention within 6 months after the baseline procedure.\n4. Predicted inability to deliver the laser fiber catheter to the target lesion due to various reasons (e.g., severe proximal tortuosity of the target vessel).","ALL","18 Years","85 Years",{"count":21,"type":22},218,"ESTIMATED","INTERVENTIONAL",[25],"NA","This prospective, multi-center clinical trial evaluates the safety and efficacy of the Coronary Laser Atherectomy System for the pretreatment of coronary artery stenosis. The study consists of two phases: a first-in-human (FIM) phase enrolling 5 subjects in a single center, and a pivotal phase, which is a prospective, multi-center, randomized controlled, non-inferiority trial enrolling 218 subjects across approximately 10 centers in China. Subjects are randomized 1:1 to receive either the investigational laser system or the control Philips CVX300 laser system for lesion pretreatment prior to PCI. The primary endpoint is clinical success, defined as successful PCI with residual stenosis \\\u003C30%, TIMI flow grade 3, and no death, myocardial infarction, or target lesion revascularization through 7 days post-procedure. Secondary endpoints include device success, procedural success, MACE, target lesion failure, and target vessel failure at 30 days and 6 months. An OCT sub-study is planned for 40 subjects.",[28],"Coronary Artery Stenosis","NOT_YET_RECRUITING","2026-07-05",{"date":32,"type":33},"2026-07-13","ACTUAL",{"date":35,"type":22},"2026-11-10",{"date":37,"type":22},"2027-12-03",{"name":39,"class":40},"Shanghai MicroPort Rhythm MedTech Co., Ltd.","INDUSTRY",{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":47,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":17,"minAge":49,"maxAge":4,"enrollmentInfo":50,"targetDuration":52,"studyType":53,"phases":4,"briefSummary":54,"conditions":55,"keywords":57,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":70},"100529743","iris-coroflex-neo-cohort-100529743","NCT06177743","IRIS-Coroflex NEO Cohort","Evaluation of Effectiveness and Safety of Coroflex ISAR NEO Stent in Routine Clinical Practice; A Multicenter, Prospective Observational Study","IRIS Coroflex","Inclusion Criteria:\n\n1. Patients ≥ 19 years old\n2. Patients receiving Coroflex ISAR NEO stents.\n3. The patient or guardian agrees to the study protocol and the schedule of clinical follow-up, and provides informed, written consent, as approved by the appropriate Institutional Review Board\u002FEthics Committee of the respective clinical site.\n\nExclusion Criteria:\n\n1. Patients with a mixture of other DESs\n2. Terminal illness with life expectancy \\\u003C1 year.\n3. Patients with cardiogenic shock","19 Years",{"count":51,"type":22},1000,"5 Years","OBSERVATIONAL","The objective of this study is to evaluate the effectiveness and safety of Coroflex ISAR NEO stents in comparison to other drug-eluting stents (DES) in real-world practice.",[28,56],"Coronary Artery Disease",[58],"percutaneous coronary intervention","RECRUITING","2026-06-23",{"date":62,"type":33},"2026-06-25",{"date":64,"type":33},"2025-01-09",{"date":66,"type":22},"2032-12-31",{"name":68,"class":69},"Seung-Jung Park","OTHER",11,{"id":72,"slug":73,"hasResults":11,"nctId":74,"briefTitle":75,"officialTitle":76,"acronym":77,"eligibilityCriteria":78,"healthyVolunteers":11,"sex":17,"minAge":79,"maxAge":4,"enrollmentInfo":80,"targetDuration":4,"studyType":23,"phases":82,"briefSummary":83,"conditions":84,"keywords":85,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":91,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":99},"100503117","diabetes-centered-evaluation-of-revascularization-strategy-of-functional-and-imaging-combined-state-of-the-art-percutaneous-coronary-intervention-or-coronary-artery-bypass-grafting-in-patients-with-diabetes-mellitus-and-multivessel-coronary-artery-disease-100503117","NCT05831085","Diabetes-Centered Evaluation of Revascularization Strategy of Functional and Imaging-CombiNEd State-of-the-Art Percutaneous Coronary Intervention or Coronary-Artery Bypass Grafting in Patients With Diabetes Mellitus and Multivessel Coronary Artery Disease","A Comparison of Imaging- and Physiology-Guided State-of-the-Art Percutaneous Coronary Intervention and Coronary-Artery Bypass Grafting in Patients With Diabetes and Three-Vessel Coronary Artery Disease: DEFINE-DM Trial (Diabetes-Centered Evaluation of Revascularization Strategy of Functional and Imaging-CombiNEd State-of-the-Art Percutaneous Coronary Intervention or Coronary-Artery Bypass Grafting in Patients With Diabetes Mellitus and Multivessel Coronary Artery Disease)","DEFINE-DM","Inclusion Criteria:\n\n1. The subject must be ≥20 years of age with angina and\u002For evidence of myocardial ischemia.\n2. Patients with type 2 diabetes based on the need for treatment with insulin or oral hypoglycemic drugs or a confirmed elevated blood glucose level (fasting plasma glucose elevation on \\>1 occasion of ≥126 mg\u002FdL \\[7.0 mmol\u002FL\\] or 2-h postprandial of ≥200 mg\u002FdL \\[11.1 mmol\u002FL\\] during oral glucose tolerance test or random plasma glucose of ≥200 mg\u002FdL \\[11.1 mmol\u002FL\\] with classic symptoms of hyperglycemia or hyperglycemic crisis or HbA1C ≥6.5% \\[48 mmol\u002Fmol\\]).\n3. Significant three-vessel CAD (defined as ≥ 50% diameter stenosis \\[DS\\] by visual estimation in each of the three major epicardial vessels or major side branches but not involving the left main coronary artery) and equivalently amenable to revascularization by means of either PCI or CABG as determined by the Heart Team at the trial site.\n4. The patient or guardian agrees to the study protocol and the schedule of clinical follow-up, and provides informed, written consent, as approved by the appropriate Institutional Review Board\u002FEthical Committee of the respective clinical site.\n\nExclusion Criteria:\n\n1. Unprotected left main coronary artery disease.\n2. The presence of complex coronary disease anatomy or lesion characteristics or other cardiac condition(s) which leads the participating interventional cardiologist to believe that PCI is not suitable (i.e. the subject should be managed with CABG or medical therapy alone).\n3. Recent ST-elevation myocardial infarction(\\\u003C5 days prior to randomization).\n4. Cardiogenic shock and\u002For need for mechanical\u002Fpharmacologic hemodynamic support.\n5. Severe left ventricular dysfunction (ejection fraction \\\u003C30%).\n6. Requirement for other cardiac or non-cardiac surgical procedure (e.g., valve replacement, aorta surgery, or carotid revascularization). However, a maze procedure or pulmonary vein isolation is allowed.\n7. Contraindication or inability to take aspirin or P2Y12 inhibitors (clopidogrel, ticagrelor, or prasugrel) for at least 6 months.\n8. Prior CABG.\n9. Extremely calcified or tortuous vessels precluding FFR measurement or intracoronary imaging evaluation.\n10. More than one major epicardial vessel which is chronically occluded; enrollment of 1 Chronic total occlusion lesion is allowed.\n11. Subjects requiring or who may require additional surgery (cardiac or noncardiac) within 1 year.\n12. End-stage renal disease requiring renal replacement therapy.\n13. Liver cirrhosis.\n14. Pregnant and\u002For lactating women.\n15. Concurrent medical condition with a limited life expectancy of less than 2 years.\n16. Patients who are actively participating in another drug or device investigational study, which have not completed the primary endpoint follow-up period. However, where at least one or more conditions are satisfied, it could be an exception according to an investigator's discretion;\n\n1\\) Participated in the observational study expected no effect on the safety and\u002For effectiveness evaluation of this trial.\n\n2\\) Screening failed before any interventional factor is involved.\n\n3\\) Participated in academic trials like strategic comparison studies conducted under standard therapy provided that there is no additional risk or a specific procedure to a subject and no interference between this trial and other studies.","20 Years",{"count":81,"type":22},1500,[25],"The objective of this randomized study was to compare outcomes of imaging-and physiology-guided state-of-the-art percutaneous coronary intervention (PCI) to coronary artery bypass grafting (CABG) in patients with diabetes and three-vessel CAD (not involving left main).",[28],[86,87,88,89,90],"Multivessel Coronary Artery Disease","state of the art","State-of-the-Art Percutaneous Coronary Intervention","Coronary-Artery Bypass Grafting","Diabetes Mellitus",{"date":92,"type":33},"2026-06-24",{"date":94,"type":33},"2024-06-14",{"date":96,"type":22},"2029-12-31",{"name":98,"class":69},"Duk-Woo Park, MD",39,{"id":101,"slug":102,"hasResults":11,"nctId":103,"briefTitle":104,"officialTitle":105,"acronym":4,"eligibilityCriteria":106,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":107,"targetDuration":4,"studyType":53,"phases":4,"briefSummary":109,"conditions":110,"keywords":114,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":121,"lastUpdatePostDateStruct":122,"startDateStruct":124,"completionDateStruct":126,"leadSponsor":128,"locationsCount":130},"100638027","ai-enhanced-single-lead-ecg-screening-for-coronary-stenosis-100638027","NCT07579624","AI-Enhanced Single-Lead ECG Screening for Coronary Stenosis","Screening for Significant Coronary Artery Stenosis Using Single-channel Electrocardiogram Analysis With Artificial Intelligence Elements","Inclusion Criteria:\n\n* Presence of written informed consent from the patient to participate in the study.\n* Age 18 years and older.\n* Outpatient visit and\u002For hospitalization at the research center with coronary visualization performed.\n\nNon-inclusion criteria:\n\n* Absence of sufficient data on coronary anatomy and stenosis significance.\n* Any conditions impairing the quality of single-channel ECG recording (Parkinson's disease, essential tremor, and others).\n* Absence of written informed consent from the patient to participate in the study.\n\nExclusion Criteria:\n\n* Patient's unwillingness to continue participation in the study.\n* Inability to perform full analysis of single-channel ECG digital characteristics.\n* Refusal of coronary visualization methods for any reason.",{"count":108,"type":22},400,"It is a prospective, controlled, single-center, non-randomized, observational study. Two patient groups are planned for inclusion: the first - 200 patients with significant coronary artery stenosis confirmed by coronary angiography (CAG) or multislice computed tomography (MSCT) results; the second - a control group consisting of 200 patients without significant stenosis according to CAG or MSCT data.\n\nAll study subjects will have a date of coronary artery imaging via CAG or MSCT with assessment of myocardial perfusion.\n\nStress echocardiography tests or fractional flow reserve (FFR) assessment will be conducted as indicated.\n\nAll patients included in the study will undergo ECG recording within 1 month before or after CAG or MSCT in standard lead I for 1 minute, followed by spectral analysis of the obtained data, which will be stored at the remote monitoring center of Sechenov University without being linked to the personal data of patients. A spectral analysis of the electrocardiogram will be performed using a continuous wavelet transform.\n\nThe result of this study will be the identification of ECG parameters that correlate with significant coronary artery stenosis.",[111,28,112,113],"Ischemic Heart Disease","Stable Angina Pectoris","Acute Coronary Syndromes",[115,111,116,117,118,119,120],"coronary","Single-Channel ECG","Artificial Intelligence","AI-Enhanced Screening","Non-Invasive Diagnostics","Angina","2026-05-06",{"date":123,"type":33},"2026-05-12",{"date":125,"type":22},"2026-05-01",{"date":127,"type":22},"2027-12-01",{"name":129,"class":69},"I.M. Sechenov First Moscow State Medical University",1,{"id":132,"slug":133,"hasResults":11,"nctId":134,"briefTitle":135,"officialTitle":136,"acronym":4,"eligibilityCriteria":137,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":138,"targetDuration":140,"studyType":53,"phases":4,"briefSummary":141,"conditions":142,"keywords":148,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":150,"lastUpdatePostDateStruct":151,"startDateStruct":153,"completionDateStruct":155,"leadSponsor":157,"locationsCount":130},"100581061","clinical-features-current-treatment-and-clinical-outcomes-in-patients-with-inr-cad-a-cohort-study-100581061","NCT06845410","Clinical Features, Current Treatment and Clinical Outcomes in Patients With INR-CAD: a Cohort Study","Clinical Features, Current Treatment and Clinical Outcomes in Patients With Inflammation-associated Non-rapidly-progressive Coronary Artery Disease (INR-CAD): a Cohort Study","Inclusion criteria\n\n1. 18 years of age or older, male or female.\n2. Negative results of urine or blood pregnancy test for females with childbearing potential (not post-menopausal or surgically sterile).\n3. Meeting the clinical diagnostic criteria for INR-CAD, including: (1) Angiographic evidence of coronary lesions (≥ 50% diameter stenosis, de novo or restenotic); (2) Evidence of chronic inflammation within 24 months: (A) Positive inflammatory markers (erythrocyte sedimentation rate \\[ESR\\], high-sensitivity C-reactive protein \\[hs-CRP\\], interleukin-6 \\[IL-6\\], tumor necrosis factor-alpha \\[TNF-α\\], et al; at least twice, ≥ 12 weeks apart), or (B) Positive autoantibodies (at least twice, ≥ 12 weeks apart), or (C) Established diagnosis of chronic inflammatory diseases (autoimmune disease, systemic vasculitis, psoriasis, tuberculosis, et al), or (D) Receiving immunosuppressive therapy (glucocorticoids, immunosuppressive agents, et al).\n4. NOT meeting the clinical diagnostic criteria for IR-CAD, including: (1) Hospitalization due to myocardial ischemia, including: (A) Typical symptoms of angina (Canadian Cardiovascular Society \\[CCS\\] III-IV), and (B) Non-invasive evidence of myocardial ischemia; (2) Angiographic evidence of new or worsened coronary lesions (de novo or restenotic) considered relevant to myocardial ischemia, which occurred: (A) Within 6 months of last coronary angiography in any patients, or (B) Within 12 months of last coronary angiography in patients receiving immunosuppressive therapy within 24 months.\n5. Received, or are receiving, or will receive the 24-month clinical follow-up defined by the clinical follow-up protocol for INR-CAD.\n\nExclusion Criteria:\n\n1. Other moderate to severe heart diseases (congenital heart disease, valvular heart disease, myocarditis, cardiomyopathy, pericardial diseases, pulmonary hypertension, heart failure, arrhythmia, et al).\n2. Active malignancy (diagnosed within 12 months or with ongoing requirement for treatment).\n3. Vital organ failure.\n4. Life expectancy \\\u003C 1 year.\n5. In pregnancy or breast-feeding, or with intention to be pregnant during the study period.\n6. Risk of non-compliance (history of drug addiction or alcohol abuse, et al).\n7. Previous enrollment in this study.\n8. Participation in another study within 30 days.\n9. Involvement in the planning and conduct of this study (applying to investigators, contract research organization staffs, study site staffs, et al).\n10. Any condition, which in the opinion of the investigators, would make it unsuitable for the patient to participate in this study.",{"count":139,"type":22},120,"24 Months","This is a cohort study to investigate the clinical features, current treatment and clinical outcomes in patients with inflammation-associated non-rapidly-progressive coronary artery disease (INR-CAD).",[56,143,28,144,145,146,147],"Coronary Artery Disease Progression","Coronary Artery Restenosis","Inflammation","Inflammatory Disease","Inflammation Vascular",[56,149,145],"Progression, Disease","2025-11-16",{"date":152,"type":33},"2025-11-19",{"date":154,"type":33},"2025-04-01",{"date":156,"type":22},"2026-12",{"name":158,"class":69},"Peking Union Medical College Hospital",{"id":160,"slug":161,"hasResults":11,"nctId":162,"briefTitle":163,"officialTitle":164,"acronym":4,"eligibilityCriteria":165,"healthyVolunteers":11,"sex":17,"minAge":166,"maxAge":167,"enrollmentInfo":168,"targetDuration":4,"studyType":53,"phases":4,"briefSummary":170,"conditions":171,"keywords":172,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":150,"lastUpdatePostDateStruct":175,"startDateStruct":176,"completionDateStruct":178,"leadSponsor":180,"locationsCount":130},"100516647","disease-characteristics-of-ir-cad-a-case-control-study-100516647","NCT06007248","Disease Characteristics of IR-CAD: a Case-control Study","Disease Characteristics of Inflammation-associated Rapidly-progressive Coronary Artery Disease (IR-CAD): a Case-control Study","Inclusion Criteria:\n\nCase group (IR-CAD patients):\n\n1. 18 years of age or older, male or female.\n2. Negative results of urine or blood pregnancy test for females with childbearing potential (not post-menopausal or surgically sterile).\n3. Prior history of coronary revascularization (PCI or coronary artery bypass graft \\[CABG\\]).\n4. Receiving standard treatment for secondary prevention of AS-CAD after the last coronary revascularization.\n5. Hospitalization due to rapidly-progressive myocardial ischemia:\n\n   * Typical symptoms of angina (Canadian Cardiovascular Society \\[CCS\\] III-IV) and non-invasive evidence of myocardial ischemia; and\n   * Occurred within 6 months or occurred on immunosuppressive therapy within 12 months of the last coronary revascularization.\n6. Angiographic evidence of new coronary lesions (de novo stenosis or restenosis) considered to be relevant to myocardial ischemia.\n7. Evidence of inflammation:\n\n   * At least one of the indexes indicating active inflammation has ever been elevated (ESR, high-sensitivity C-reactive protein \\[hs-CRP\\], interleukin \\[IL\\]-6, tumor necrosis factor \\[TNF\\]-α, ferritin, et al); or\n   * Established diagnosis of systemic autoimmune disease or systemic vasculitis; or\n   * Receiving immunosuppressive therapy.\n\nControl group (AS-CAD patients):\n\n1. ≥ 45 and \\\u003C 65 years of age (based on the age distribution of the patients currently enrolled in the IR-CAD cohort study), male or female.\n2. Negative results of urine or blood pregnancy test for females with childbearing potential (not post-menopausal or surgically sterile).\n3. Currently, 12±6 months after the last PCI.\n4. Receiving standard treatment for secondary prevention of AS-CAD after the last PCI.\n5. Coronary angiography and\u002For optical coherence tomography (OCT) performed during the present hospitalization.\n6. No evidence of rapidly-progressive myocardial ischemia, which is defined as follows:\n\n   * Typical symptoms of angina (Canadian Cardiovascular Society \\[CCS\\] III-IV) and non-invasive evidence of myocardial ischemia; and\n   * Occurred within 6 months or occurred on immunosuppressive therapy within 12 months of the last PCI.\n7. No angiographic evidence of new coronary lesions (de novo stenosis or restenosis) considered to be relevant to myocardial ischemia.\n\nExclusion Criteria:\n\nCase group (IR-CAD patients):\n\n1. Coronary restenosis due to mechanical factors (stent under-expansion, stent mal-apposition, stent rupture, et al).\n2. Other moderate to severe heart diseases (congenital heart disease, valvular heart disease, myocarditis, cardiomyopathy, pericardial diseases, pulmonary hypertension, heart failure, arrhythmia, et al).\n3. Active acute or chronic infection (human immunodeficiency virus \\[HIV\\], tuberculosis, et al).\n4. Active malignancy (diagnosed within 12 months or with ongoing requirement for treatment).\n5. Vital organ failure.\n6. Life expectancy \\\u003C 1 year.\n7. Contraindications for or intolerance to treatment for secondary prevention of AS-CAD, contrast agents, glucocorticoids, immunosuppressive agents.\n8. In pregnancy or breast-feeding, or with intention to be pregnant during the study period.\n9. Risk of non-compliance (history of drug addiction or alcohol abuse, et al).\n10. Previous enrollment in this study.\n11. Participation in another study within 30 days.\n12. Involvement in the planning and conduct of this study (applying to investigators, contract research organization staffs, study site staffs, et al).\n13. Any condition, which in the opinion of the investigators, would make it unsuitable for the patient to participate in this study.\n\nControl group (AS-CAD patients):\n\nThe same as those for the case group (IR-CAD patients).","45 Years","64 Years",{"count":169,"type":22},30,"The present case-control study is designed to investigate the disease characteristics of IR-CAD by comparing the demographics, clinical features, lab results, imaging findings, and prior treatment between 20 patients with IR-CAD and 10 patients with AS-CAD.",[56,28,144,143,145,146,147],[56,173,149,145,174],"Coronary Revascularization","Characteristics Disease",{"date":152,"type":33},{"date":177,"type":33},"2023-11-02",{"date":179,"type":22},"2026-09",{"name":158,"class":69},{"id":182,"slug":183,"hasResults":11,"nctId":184,"briefTitle":185,"officialTitle":186,"acronym":4,"eligibilityCriteria":187,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":188,"targetDuration":140,"studyType":53,"phases":4,"briefSummary":189,"conditions":190,"keywords":191,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":150,"lastUpdatePostDateStruct":192,"startDateStruct":193,"completionDateStruct":195,"leadSponsor":196,"locationsCount":130},"100505364","efficacy-and-safety-of-comprehensive-treatment-in-patients-with-ir-cad-a-self-controlled-cohort-study-100505364","NCT05860400","Efficacy and Safety of Comprehensive Treatment in Patients With IR-CAD: a Self-controlled Cohort Study","Efficacy and Safety of Comprehensive Treatment in Patients With Inflammation-associated Rapidly-progressive Coronary Artery Disease (IR-CAD): a Self-controlled Cohort Study","Inclusion Criteria:\n\n1. Fulfilling all the following criteria before initiation of comprehensive treatment:\n\n   1.1 18 years of age or older, male or female.\n\n   1.2 Negative result of urine or blood pregnancy test for females with childbearing potential (not post-menopausal or surgically sterile).\n\n   1.3 Prior history of coronary revascularization (percutaneous coronary intervention \\[PCI\\] or coronary artery bypass graft \\[CABG\\]).\n\n   1.4 Receiving standard treatment for secondary prevention of atherosclerotic coronary artery disease (AS-CAD) after the last coronary revascularization.\n\n   1.5 Hospitalization due to rapidly-progressive myocardial ischemia:\n   * Typical symptoms of angina (Canadian Cardiovascular Society \\[CCS\\] III-IV) and non-invasive evidence of myocardial ischemia; and\n   * Occurred within 6 months or occurred on immunosuppressive therapy within 12 months of the last coronary revascularization.\n\n   1.6 Angiographic evidence of new coronary lesions (de novo stenoses or restenoses):\n   * Occurred after the last coronary revascularization; and\n   * Related to myocardial ischemia (location, extent, severity, et al).\n\n   1.7 Evidence of inflammation:\n   * At least one of the markers indicating active inflammation has ever been elevated (erythrocyte sedimentation rate \\[ESR\\], high-sensitivity C-reactive protein \\[hs-CRP\\], interleukin \\[IL\\]-6, tumor necrosis factor \\[TNF\\]-α, ferritin, et al); or\n   * Established diagnosis of systemic autoimmune disease or systemic vasculitis; or\n   * Receiving immunosuppressive therapy.\n2. Receiving comprehensive treatment, including ischemia-driven PCI which was performed no earlier than 40 days of the initiation of immunosuppressive therapy.\n\nExclusion Criteria:\n\n1. Coronary restenosis due to mechanical factors (stent under-expansion, stent mal-apposition, stent rupture, et al).\n2. Other moderate to severe heart diseases (congenital heart disease, valvular heart disease, myocarditis, cardiomyopathy, pericardial diseases, pulmonary hypertension, heart failure, arrhythmia, et al).\n3. Active acute or chronic infection (human immunodeficiency virus \\[HIV\\], tuberculosis, et al).\n4. Active malignancy (diagnosed within 12 months or with ongoing requirement for treatment).\n5. Vital organ failure.\n6. Life expectancy \\\u003C 1 year.\n7. Contraindications for or intolerance to treatment for secondary prevention of AS-CAD, contrast agents, glucocorticoids, immunosuppressive agents.\n8. In pregnancy or breast-feeding, or with intention to be pregnant during the study period.\n9. Risk of non-compliance (history of drug addiction or alcohol abuse, et al).\n10. Previous enrollment in this study.\n11. Participation in another study within 30 days.\n12. Involvement in the planning and conduct of this study (applying to investigators, contract research organization staffs, study site staffs, et al).\n13. Any condition, which in the opinion of the investigators, would make it unsuitable for the patient to participate in this study.",{"count":99,"type":22},"This is a self-controlled cohort study to evaluate the efficacy and safety of comprehensive treatment in patients with inflammation-associated rapidly-progressive coronary artery disease (IR-CAD) by comparing the study endpoints before treatment with those after treatment in the same group of patients.",[56,28,144,143,145,146,147],[56,173,149,145],{"date":152,"type":33},{"date":194,"type":33},"2023-05-17",{"date":179,"type":22},{"name":158,"class":69},{"id":198,"slug":199,"hasResults":11,"nctId":200,"briefTitle":201,"officialTitle":202,"acronym":203,"eligibilityCriteria":204,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":205,"enrollmentInfo":206,"targetDuration":4,"studyType":23,"phases":208,"briefSummary":209,"conditions":210,"keywords":213,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":220,"lastUpdatePostDateStruct":221,"startDateStruct":223,"completionDateStruct":225,"leadSponsor":227,"locationsCount":4},"100600492","to-evaluate-the-performance-and-safety-of-risor-crest-everolimus-eluting-coronary-stent-system-100600492","NCT07098195","To Evaluate the Performance and Safety of RisoR Crest Everolimus Eluting Coronary Stent System","An OPen-label, Multicentre, Single Arm, Clinical InvestigatIon to Evaluate PerFormance and Safety of RIsoR Crest EveRolimus Eluting Coronary Stent System","PACIFIER","Inclusion Criteria:\n\n1. Age more than 18 years\n2. All Genders (Males, Females, Transgenders, Non binary)\n3. Patient or legally authorized representative (LAR) agrees to participate by signing the informed consent form.\n4. Patient with coronary artery disease eligible for percutaneous coronary intervention (PCI) as per regional or hospital's standard practices guidelines for PCI (For Europe, as per ESC guidelines)\n5. Patient with coronary artery disease having one or more de novo or in - stent stenosis lesions in native coronary artery with a visually estimated diameter stenosis ≥70%.\n6. Patients with Reference vessel diameter of 2.0 to 4.5 mm\n7. Patients with lesion length less than 48 mm\n\nExclusion Criteria:\n\n1. Pregnant and lactating females\n2. Candidates for emergency bypass Surgery\n3. Patients corresponding to the criteria of a vulnerable population (Vulnerable subjects, including patients who are unable to fully understand all aspects of the investigation, patients who could be manipulated or unduly influenced, patients lacking capacity in the informed consent procedure and patients with dementia and cognitive impairment, patients under social security, imprisonment etc.)\n4. Known congestive heart failure (NYHA IV) or left ventricular ejection fraction (LVEF) less than 30 Percent\n5. Patients with known hypersensitivity or allergies to aspirin, heparin, clopidogrel, ticlopidine, Everolimus or similar drugs, or any other analogue or derivative, cobalt, chromium, nickel, molybdenum or contrast media\n6. Current medical condition with a life expectancy of less than 12 months\n7. Patient who have current unstable arrhythmias\n8. Patient previously undergone CABG.\n9. Left Main Coronary Artery lesion\n10. Patients with Cardiogenic shock, systemic bleeding and coagulation disorders, intracranial bleeding, Renal insufficiency requiring dialysis, Acute or chronic renal dysfunction (serum creatinine \\>2.0mg\u002Fdl or 150 μmol\u002FL), peripheral vascular diseases, cancer, etc. and patients who are planning to undergo surgery within 360 days of the index procedure\n11. Patients with platelet count \\\u003C100,000 cells\u002Fmm3 or \\>700,000 cells\u002Fmm3 or a WBC \\\u003C3,000 cells\u002Fmm3","99 Years",{"count":207,"type":22},2000,[25],"The study will evaluate the performance and safety of RisoR Crest Everolimus Eluting Coronary Stent System. A total of 2000 participants will be included in the study from India and Italy.",[56,28,211,212],"Percutaneous Coronary Intervention","de Novo Lesions in Native Coronary Arteries",[214,215,216,217,218,219],"RisoR Crest","Everolimus Eluting Stent","Poly Medicure Private Limited","Drug Eluting Stent","Biodegradable Polymer","Pacifier","2025-07-29",{"date":222,"type":33},"2025-08-01",{"date":224,"type":22},"2025-08-18",{"date":226,"type":22},"2028-01-17",{"name":228,"class":40},"Poly Medicure Limited",{"id":230,"slug":231,"hasResults":11,"nctId":232,"briefTitle":233,"officialTitle":233,"acronym":234,"eligibilityCriteria":235,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":236,"targetDuration":4,"studyType":53,"phases":4,"briefSummary":238,"conditions":239,"keywords":4,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":242,"lastUpdatePostDateStruct":243,"startDateStruct":245,"completionDateStruct":247,"leadSponsor":249,"locationsCount":130},"100581025","vessel-imaging-using-optical-coherence-tomography-for-plaque-morphology-and-vessel-fractional-flow-reserve-100581025","NCT06844942","Vessel Imaging Using Optical Coherence Tomography for Plaque Morphology and Vessel Fractional Flow Reserve","VISION-FFR","Inclusion Criteria:\n\n* 18 years or older\n* Chronic coronary syndrome defined as presence of chest pain ranked 2-3 in the Canadian Cardiovascular Society classification or positive ischemia test (exercise test, single photon emission tomography (SPECT)\n* Intermediate grade coronary stenosis of 40-80% assessed visually in coronary angiography and OCT examination The patient is willing to participate in the study and has provided a written informed consent\n\nExclusion Criteria:\n\n* Acute coronary syndrome\n* Proximal left main lesion\n* Ostial right coronary artery lesion\n* Bypass of the assessed vessel\n* Contraindications for adenosine administration\n* Hemodynamic instability\n* Heart insufficiency in New York Heart Association (NYHA) class IV scale\n* Acute renal insufficiency\n* Pregnancy",{"count":237,"type":22},200,"The aim of this prospective, investigator-initiated study is to evaluate the diagnostic accuracy and correlations between mopphometric indices: luminal and qualitative parameters assessed by optical coherence tomography (OCT) including minimal lumen area, plaque type, presence of thin cap fibroatheroma and a functional index - angiography based vessel fractional flow reserve (vFFR) among patients with chronic coronary syndrome identified with intermediate grade coronary stenosis.",[56,28,240,241],"Tomography, Optical Coherence","3D-angio-based FFR","2025-02-19",{"date":244,"type":33},"2025-02-25",{"date":246,"type":33},"2020-09-20",{"date":248,"type":22},"2029-01-31",{"name":250,"class":69},"Medical University of Warsaw",{"id":252,"slug":253,"hasResults":11,"nctId":254,"briefTitle":255,"officialTitle":255,"acronym":256,"eligibilityCriteria":257,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":258,"targetDuration":4,"studyType":23,"phases":260,"briefSummary":261,"conditions":262,"keywords":264,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":272,"lastUpdatePostDateStruct":273,"startDateStruct":275,"completionDateStruct":277,"leadSponsor":279,"locationsCount":130},"100449543","complete-functional-assessment-of-intermediate-coronary-artery-stenosis-before-and-after-transcatheter-aortic-valve-implantation-tavi-in-patients-with-severe-symptomatic-aortic-valve-stenosis-100449543","NCT05133843","Complete Functional Assessment of Intermediate Coronary Artery Stenosis Before and After Transcatheter Aortic Valve Implantation (TAVI) in Patients With Severe Symptomatic Aortic Valve Stenosis","CHOICE-FR","Inclusion Criteria:\n\n* Age \\>18 years\n* Willing to participate and able to understand, read and sign the informed consent document before the planned procedure\n* Severe symptomatic aortic stenosis with indication for TAVI according to current guidelines deemed by the Heart Team\n* Patients who have undergone coronary CT angiography before TAVI in which CAD could not be ruled out\n* CAD in one or more native major epicardial vessels or their branches by coronary angiogram with visually assessed coronary stenosis, in which the physiological severity of the lesion is in question (typically 40-90% diameter stenosis).\n* Eligible for invasive coronary angiography and functional assessment (FFR, RFR, CFR and IMR)\n* Eligible for coronary CT-angiography and functional assessment (CT-FFR)\n\nExclusion Criteria:\n\n* Patients whose CT-angiography was determined to be non-diagnostic\u002Funreadable during its evaluation\n* Previous coronary artery bypass grafting with patent grafts to the interrogated vessel\n* Patients with severe lesions with a diameter stenosis ≥ 90%, flow-limiting lesions, or a significant left main coronary artery stenosis\n* Critical coronary artery disease deemed by the Heart Team to require immediate revascularization\n* Contraindication to adenosine (e.g. bronchial asthma)\n* Chronic renal impairment with severe reduction of glomerular filtration rate (eGFR \\\u003C30 ml\u002Fmin)\n* Presence of cardiogenic shock\n* Participation in another interventional study involving the left heart or coronary arteries",{"count":259,"type":22},50,[25],"The purpose of the current study is to assess complete coronary physiology (FFR, RFR, CFR, IMR, and CT-FFR) in TAVI candidates with intermediate coronary artery stenosis before and 6 months after TAVI. This aims to determine how TAVI affects coronary blood flow and coronary microcirculatory function after longer-term follow-up, and how these effects influence FFR and RFR values. In addition, it is aimed to correlate invasive functional testing (FFR and RFR) with non-invasive CT-FFR before and 6 months after TAVI.",[28,263],"Transcatheter Aortic Valve Implantation",[28,265,266,267,268,269,270,271],"transcatheter aortic valve implantation","coronary physiology","coronary blood flow","coronary microcirculatory function","non-invasive CT-FFR","fractional flow reserve","resting full cycle ratio","2024-11-22",{"date":274,"type":33},"2024-11-25",{"date":276,"type":33},"2021-09-29",{"date":278,"type":22},"2025-09-30",{"name":280,"class":69},"Helios Health Institute GmbH",{"id":282,"slug":283,"hasResults":11,"nctId":284,"briefTitle":285,"officialTitle":285,"acronym":286,"eligibilityCriteria":287,"healthyVolunteers":288,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":289,"targetDuration":4,"studyType":53,"phases":4,"briefSummary":291,"conditions":292,"keywords":4,"overallStatus":59,"whyStopped":4,"lastUpdateSubmitDate":293,"lastUpdatePostDateStruct":294,"startDateStruct":296,"completionDateStruct":298,"leadSponsor":300,"locationsCount":130},"100372188","breathing-maneuver-induced-myocardial-oxygenation-reserve-validated-by-ffr-b-more-100372188","NCT04126148","Breathing-Maneuver-Induced Myocardial Oxygenation Reserve Validated by FFR (B-MORE)","B-MORE","Inclusion Criteria:\n\nHealthy Participants\n\n* Age: \\> 40y\n* No known current or pre-existing significant medical problems that would affect the cardiovascular or respiratory system.\n\nCAD Patients\n\n* Age \\> 18 y\n* Indication for invasive coronary angiography based on symptoms and a test positive for inducible coronary ischemia, or previous coronary angiography.\n\nExclusion Criteria:\n\nALL participants:\n\n* General MRI contraindications: Pacemakers, defibrillating wires, implanted defibrillators, intracranial aneurysm clips, metallic foreign bodies in the eyes, knowledge or suspicion of pregnancy.\n* Consumption of caffeine (coffee, tea, cocoa, chocolate, \"energy drink\") during the 12 hours prior to the exam.\n* Regular nicotine consumption during the last 6 months.\n\nPatients only\n\n* Vasoactive medication (e.g. nitro) during the 12 hours prior to the exam Contraindications to adenosine (2nd or 3rd A-V block, sinus node disease, asthma, bronchoconstrictive diseases).\n* Acute Coronary Syndrome (ACS), or previous Coronary Artery Bypass Surgery\n* Previous myocardial infarction within 1 month\n* Clinically unstable condition\n* Significant or uncontrolled arrhythmia",true,{"count":290,"type":22},350,"The study aims to determine a diagnostic marker for regionally impaired myocardial oxygenation response in patients with suspected coronary artery stenosis.",[28],"2024-10-22",{"date":295,"type":33},"2024-10-24",{"date":297,"type":33},"2019-07-04",{"date":299,"type":22},"2024-12",{"name":301,"class":69},"McGill University Health Centre\u002FResearch Institute of the McGill University Health Centre",{"id":303,"slug":304,"hasResults":11,"nctId":305,"briefTitle":306,"officialTitle":307,"acronym":308,"eligibilityCriteria":309,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":310,"targetDuration":4,"studyType":53,"phases":4,"briefSummary":312,"conditions":313,"keywords":314,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":316,"lastUpdatePostDateStruct":317,"startDateStruct":319,"completionDateStruct":321,"leadSponsor":322,"locationsCount":130},"100475606","inav-based-automated-coronary-magnetic-resonance-angiography-for-the-detection-of-coronary-artery-stenosis-100475606","NCT05473117","iNav-based, Automated Coronary Magnetic Resonance Angiography for the Detection of Coronary Artery Stenosis","iNav-based, Automated Coronary Magnetic Resonance Angiography for the Detection of Coronary Artery Stenosis (iNav-AUTO CMRA)","iNav-AUTO CMRA","Inclusion Criteria:\n\n* Inclusion Criteria:\n* ≥18 years old\n* Subject has provided informed written consent\n* BMI \\\u003C 35\n* Sinus Rhythm\n* Stable symptom at time of inclusion\n* Undergoing CCTA within 28 days\n\nExclusion Criteria:\n\n* Any contraindication to CMR\n* Previous coronary revascularisation\n* Inability to take sublingual nitroglycerin\n* Irregular heart rate",{"count":311,"type":22},160,"Ischaemic Heart Disease (IHD) is the worlds leading cause of death. IHD is often caused by a narrowing of the coronary arteries, which prevents blood from flowing to the heart muscle, causing pain and damage to the heart. If an individual has a myocardial infarction (MI), parts of the heart that are damaged cannot be repaired. Therefore, it is important to identify and treat the narrowing of the arteries before an MI occurs.\n\nAt present there are 2 main methods of identifying narrowing of the arteries. The first is an invasive procedure, the other using a CT scan. Whilst both methods are effective, they entail risk. The invasive procedure can damage the coronary arteries, whilst the CT scan exposes patients to radiation and contrast, which can increase the risk of cancer and allergic reactions.\n\nMagnetic Resonance (MR) scanning is an alternative to these methods, but it has been limited in use in the past due, in part, to the high technical knowledge required to obtain images. In addition, there is a degree of subjectivity in the selection of the mid-diastolic rest period, potentially affecting consistency of results. This means it is difficult to use in a day-to-day hospital environment. However, recent technological developments using artificial intelligence mean that images can be acquired in a more automated and consistent fashion. This new scan has yet to be tested in a clinical trial.\n\nTherefore, the objective of the clinical study is to test this new scan to determine its efficacy. 230 patients at 5 sites at risk of coronary artery disease, who have been referred for invasive coronary angiography, will undergo both their angiography and the new MR scan. The MR scan will then be compared to CCTA for diagnostic accuracy and image quality.\n\nThe investigators hypothesise that the new MR scan will have the same diagnostic accuracy as invasive coronary angiography, with no differences in interpretation of the images across the 5 different hospitals.\n\nIf proven effective, this would demonstrate that MR scanning of the coronary arteries could prove a safe, clinically useful alternative to both CT scanning and invasive assessment of coronary artery narrowing. In addition, if there is no difference across different locations, it would demonstrate that these scans can be performed consistently, facilitating implementation on a healthcare-system wide basis.",[28],[315,28,117],"Coronary Magnetic Resonance Angiography","2023-06-19",{"date":318,"type":33},"2023-06-22",{"date":320,"type":22},"2024-06",{"date":156,"type":22},{"name":323,"class":69},"Aarhus University Hospital"]